Jon Siegal

Jon is a seasoned and versatile communications executive with expertise in the pharmaceutical, biotechnology, advocacy, medical device, and diagnostic industries. A senior leader, Jon has devoted much of his career to setting strategy and delivering best-in-class media campaigns that deliver results across multiple channels and verticals within the U.S. Health sector. As a creative storyteller, he excels at finding interesting story angles within complicated topics. 

Jon’s experience includes corporate and product communications, as well as disease awareness campaigns and consumer communications for organizations ranging from cutting-edge startups to emerging growth companies to global market leaders. His understanding of the evolving media landscape has enabled him to land impactful coverage in a broad spectrum of media outlets that range the gamut from syndicated wire services to top-tier consumer and business publications to important trade and policy outlets. 

Recently, Jon directed media strategy for the FDA approval of JOURNAVX, the first non-opioid pain drug in 25 years. He also led media for the rebranding of the Leukemia & Lymphoma Society into Blood Cancer United. In addition, he has led media strategy for Moderna’s COVID-19 vaccine for several years.

Prior to joining Weber in 2019, Jon served as a senior media lead at MSL and prior to that, Schwartz Communications (acquired by MSL). Jon graduated from the University of Massachusetts (Amherst) and currently resides in southeastern Massachusetts.